Challenges and opportunities in improving the management of atrial fibrillation: recent research advances and their clinical translation

Atrial fibrillation (AF) is a problem of major clinical importance, accounting for about 9 million cases in the European Union in 2010 with projections for an almost doubling by 2060.1 The worldwide economic burden of AF was estimated at 6 million disability-adjusted life-years of lost productivity in 2017.2 The average 3-year societal cost per patient in Denmark attributable to AF over the period 2001 –2012 was estimated to be of the order of 25 000 Euros ($30 000), providing an overall cost burden in Europe of the order of 10 billion Euros.3 Clearly, AF is a major issue at the level of public health and economic burden, motivating the regular establishment of detailed society guidelines, including two in the last year.4,5
Source: Cardiovascular Research - Category: Cardiology Source Type: research